S-8 1 2023_rxsight_s-8.htm S-8 S-8

As filed with the Securities and Exchange Commission on March 6, 2023
Registration No. 333-

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM S‑8

REGISTRATION STATEMENT

UNDER

THE SECURITIES ACT OF 1933

 

RXSIGHT, INC.

(Exact name of Registrant as specified in its charter)

 

 

 

Delaware

 

94-3268801

(State or other jurisdiction of
incorporation or organization)

 

(I.R.S. Employer
Identification Number)

 

100 Columbia

Aliso Viejo, CA 92656

(949) 521-7830

(Address, including zip code, and telephone number, including area code, of Registrant’s principal executive offices)

 

2021 Equity Incentive Plan

(Full title of the plan)

 

Ron Kurtz, M.D.

President and Chief Executive Officer

RxSight, Inc.

100 Columbia

Aliso Viejo, CA 92656

(949) 521-7830

 

(Name, address, including zip code, and telephone number, including area code, of agent for service)

Copies to:

 

 

 

Martin J. Waters

Robert L. Wernli, Jr.

Wilson Sonsini Goodrich & Rosati, P.C.

12235 El Camino Real

San Diego, CA 92130

(858) 350-2300

 

Shelley Thunen

Chief Financial Officer

RxSight, Inc.

100 Columbia

Aliso Viejo, CA 92656

(949) 521-7830

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer

 

Accelerated filer

Non-accelerated filer

 

Smaller reporting company

 

 

 

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☒

 


PART I



INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS

 

This Registration Statement on Form S-8 (the “Registration Statement”) is filed by RxSight, Inc. (the “Registrant”) for the purpose of registering 1,130,735 additional shares of common stock of the Registrant that may be issued pursuant to the RxSight, Inc. 2021 Equity Incentive Plan.

In accordance with General Instruction E to Form S-8, the contents of the previous Registration Statements on Form S-8 filed by the Registrant with the Securities and Exchange Commission (the “SEC”) on July 30, 2021 (File No. 333-258292) and Form S-8 filed by the Registrant with the SEC on March 8, 2022 (File No. 333-263374) are incorporated by reference into this Registration Statement.

 



PART II

 

INFORMATION REQUIRED IN REGISTRATION STATEMENT

 

Item 3. Incorporation of Documents by Reference.

 

The Registrant hereby incorporates by reference into this Registration Statement the following documents previously filed with the SEC:

(1)
The Registrant’s Annual Report on Form 10-K for the fiscal year ended December 31, 2022, filed with the Commission on March 6, 2023 (the “Annual Report”);
(2)
All other reports filed pursuant to Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), since the end of the fiscal year covered by the Annual Report (other than the portions of these documents not deemed to be filed); and
(3)
The description of the Registrant’s Common Stock contained in the Registrant’s Registration Statement on Form 8-A (File No. 001-40690) filed with the Commission on July 28, 2021, pursuant to Section 12(b) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), including any amendment or report filed for the purpose of updating such description.

All documents filed by the Registrant pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act on or after the date of this Registration Statement and prior to the filing of a post-effective amendment to this Registration Statement that indicates that all securities offered have been sold or that deregisters all securities then remaining unsold shall be deemed to be incorporated by reference in this Registration Statement and to be part hereof from the date of filing of such documents; provided, however, that documents or information deemed to have been furnished and not filed in accordance with the rules of the Commission shall not be deemed incorporated by reference into this Registration Statement. Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or in any subsequently filed document which also is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.

 

Item 7. Exemption from Registration Claimed.

 

Not applicable.

 


Item 8. Exhibits.

 

Exhibit

 

Incorporated by Reference

Number

Description

Form

File No.

Exhibit

Filing Date

 

 

 

 

 

 

4.1

Specimen common stock certificate of the Registrant

 S-1/A

 333-257790

 4.2

 July 26, 2021

4.2

2021 Equity Incentive Plan, and form agreements thereunder

 10-Q

  001-40690

 10.2

  November 10, 2021

5.1*

Opinion of Wilson Sonsini Goodrich & Rosati, Professional Corporation

 

 

 

 

23.1*

Consent of Independent Registered Public Accounting Firm

 

 

 

 

23.2

Consent of Wilson Sonsini Goodrich & Rosati, Professional Corporation (contained in Exhibit 5.1 hereto)

 

 

 

 

24.1*

Power of Attorney (contained on signature page hereto)

 

 

 

 

107*

Filing Fee Table

 

 

 

 

*

Filed herewith.

 

 

 

 

 

 

 


SIGNATURES

 

Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Aliso Viejo, State of California, on March 6, 2023.

 

 

 

 

RXSIGHT, INC.

 

 

By:

 

/s/ Ron Kurtz, M.D.

 

 

Ron Kurtz, M.D.

 

 

President and Chief Executive Officer

 

POWER OF ATTORNEY

 

KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Ron Kurtz, M.D. and Shelley Thunen as his or her true and lawful attorneys-in-fact and agents, with full power of substitution and substitution, for him or her and in their name, place and stead, in any and all capacities, to sign this Registration Statement and any and all amendments thereto (including post-effective amendments), and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact, and agents or any of them, or his or her substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

 

Pursuant to the requirements of the Securities Act of 1933, this registration statement on Form S-8 has been signed by the following persons in the capacities and on the dates indicated.

 

Signature

 

Title

 

Date

 

 

 

 

 

/s/ Ron Kurtz, M.D.

 

President, Chief Executive Officer and Director (Principal Executive Officer)

 

March 6, 2023

Ron Kurtz, M.D.

 

 

 

 

 

 

/s/ Shelley Thunen

 

Chief Financial Officer

(Principal Financial and Accounting Officer)

 

March 6, 2023

Shelley Thunen

 

 

 

 

 

 

/s/ J. Andy Corley

 

Chair of the Board

 

March 6, 2023

J. Andy Corley

 

 

 

 

 

 

/s/ William J. Link, Ph.D.

 

Director

 

March 6, 2023

William J. Link, Ph.D.

 

 

 

 

 

 

/s/ Juliet Tammenoms Bakker

 

Director

 

March 6, 2023

Juliet Tammenoms Bakker

 

 

 

 

 

 

/s/ Julie Andrews

 

Director

 

March 6, 2023

Julie Andrews

 

 

 

 

 

 

 

/s/ Robert Palmisano

 

Director

 

March 6, 2023

Robert Palmisano

 

 

 

 

 

 

 

 

 

/s/ Robert Warner

 

Director

 

March 6, 2023

Robert Warner

 

 

 

 

 

 

 

 

 

/s/ Shweta Singh Maniar

 

Director

 

March 6, 2023

Shweta Singh Maniar

 

 

 

 

 

 

 

 

 

/s/ Tamara R. Fountain, M.D.

 

Director

 

March 6, 2023

Tamara R. Fountain, M.D.